Litcius/Paper detail

LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)

Caicun Zhou, Lin Wu, Yun Fan, Zhaoguang Wang, Luwei Liu, G. Chen, L. Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Baopu Li, J. Li, Min Fan, W. Zhang, Wei Yang, Shuxiao Wang, Hui Zhou

2020Annals of Oncology17 citationsDOI

Topics & Concepts

MedicineInternal medicineGemcitabineCarboplatinInterim analysisClinical endpointGastroenterologyPlaceboLung cancerProgression-free survivalNauseaChemotherapyCisplatinOncologyRandomized controlled trialSurgeryPathologyAlternative medicineCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer Genomics and Diagnostics
LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC) | Litcius